Rosenthal D I, Glatstein E
Department of Radiation Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas 75235-8590.
Ann Med. 1994 Dec;26(6):405-9. doi: 10.3109/07853899409148361.
This is a review of photodynamic therapy, which is a classic binary system involving the use of a photosensitizer and light of very specific wavelength, consistent with the absorption characteristics of that sensitizer. As a binary system, its effects are almost entirely limited to tumour cells, but the major drawback is its limited penetration because it utilizes physical light within the visible spectrum. For Photofrin II, which is the only approved sensitizer for clinical use in this country, the effects are limited to approximately 0.5 cm or less, depending on the tissue and the amount of blood, etc. Newer sensitizers offer more penetration and the opportunity to repeat treatments, because the newer sensitizers do not have the very long (up to 10 weeks) period of enhanced skin sensitivity to sunlight. A summary of the results of photodynamic therapy by individual sites is included. The use of newer sensitizers, which represent much purer substances than Photofrin II, should give an opportunity for repeated treatments, which should eventually make this form of treatment far more important than it has been up to now.
这是一篇关于光动力疗法的综述，它是一种经典的二元系统，涉及使用光敏剂和与该光敏剂吸收特性一致的特定波长的光。作为二元系统，其作用几乎完全局限于肿瘤细胞，但主要缺点是其穿透有限，因为它利用的是可见光谱内的物理光。对于该国唯一获批用于临床的光敏剂卟吩姆钠（Photofrin II），其作用范围限于约0.5厘米或更小，这取决于组织、血液量等因素。新型光敏剂具有更强的穿透性且有机会重复治疗，因为新型光敏剂不会出现皮肤对阳光敏感性增强长达10周的漫长时期。文中包含了按不同部位进行光动力疗法的结果总结。使用比卟吩姆钠纯度更高的新型光敏剂，应该能提供重复治疗的机会，这最终可能使这种治疗方式比目前更为重要。
